U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07007117) titled 'PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma' on May 28.
Brief Summary: This is a first in human dose escalation trial to determine the safety of administering PHOX2B PC-CAR T cells in patients with advanced, high-risk neuroblastoma.
Study Start Date: June 25
Study Type: INTERVENTIONAL
Condition:
Refractory Neuroblastoma
Relapsed Neuroblastoma
High-Risk Neuroblastoma
Intervention:
BIOLOGICAL: PHOX2B PC-CAR T Cells
The PHOX2B PC-CAR T cell investigational product is comprised of autologous human T cells that have been genetically modified to express a a PHOX2B-targeting chimeric antigen receptor (CAR) transgene.
Recruitmen...